FDA accepts a new formulation of piflufolastat F 18, enhancing prostate cancer imaging access and efficiency, with a target ...

Roxadustat advances as a promising oral treatment for anemia in lower-risk myelodysplastic syndromes, targeting high ...

A new FDA-approved trial explores innovative treatments for recurrent glioblastoma, offering hope for patients facing this ...

FDA expands tocilizumab-anoh's indication for treating cytokine release syndrome, enhancing treatment options for patients ...

The FDA fast-tracks birelentinib, a dual inhibitor for relapsed CLL/SLL, promising new hope for patients facing treatment ...

The FDA approves the Embrace Hydrogel Embolic System, offering a groundbreaking treatment for hypervascular tumors in ...

During a live event, Tony Philip, MD, recommended tailored imaging intervals and avoiding surgery and radiation for desmoid ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

During a live event, Matthew Lunning, DO, and participants discussed the process of determining if patients with DLBCL should ...

The RESONATE-2 trial reveals ibrutinib's long-term efficacy and safety in treating CLL/SLL, especially for high-risk patients ...

FDA accelerates approval of dordaviprone, the first targeted therapy for aggressive diffuse midline glioma, offering hope for ...

Hemispherian's GLIX1 gains FDA approval for glioblastoma trials, promising a novel therapy targeting DNA repair in tumor ...